Flame Biosciences raises $100M to advance mAbs trials

By The Science Advisory Board staff writers

September 30, 2020 -- Flame Biosciences announced the completion of a $100 million common stock financing to advance clinical trials for monoclonal antibodies (mAbs).

Currently, Flame is developing mAbs that bind and neutralize interleukin-1β (IL-1β) with the intention of treating multiple diseases, specifically cancer. Clinical research shows that IL-1β is a key mediator of the chronic inflammation that causes tumor growth, and Flame's IL-1β neutralizing antibody FL-10 has the potential to treat cancer effectively, according to the company.

FL-101 will enter the clinic for proof-of-concept testing in patients with non-small cell lung cancer in the first half of 2021.


Copyright © 2020 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.